LeMaitre Vascular (STU:LHU) Research & Development: €13.3 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:LHU LeMaitre Vascular Inc STU:LHU
98 GF Score
Price €69.00
GF Value €81.33
Valuation Modestly Undervalued
View Full Analysis

What is LeMaitre Vascular Research & Development?

LeMaitre Vascular STU:LHU +0.73% 98 Research & Development is €13.3 Mil as of Jun. 2026. GuruFocus rates STU:LHU with a GF Score™ of 98/100 and a GF Value™ of €81.33 (Modestly Undervalued).

Research & Development is the aggregate amount of research and development expenses during the year. LeMaitre Vascular's Research & Development for the three months ended in Jun. 2026 was €4.2 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was €13.3 Mil.

LeMaitre Vascular  (STU:LHU) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

LeMaitre Vascular Research & Development Related Terms

LeMaitre Vascular Research & Development Historical Data

* Premium members only.

The historical data trend for LeMaitre Vascular's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LeMaitre Vascular Research & Development Chart

LeMaitre Vascular Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.44 12.55 15.56 14.95 12.08

LeMaitre Vascular Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.07 2.53 3.02 3.51 4.21
STU:LHU
98GF Score
LeMaitre Vascular Inc STU:LHU
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LeMaitre Vascular Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €13.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €13.3 Mil mean?
LeMaitre Vascular (STU:LHU) has a Research & Development of €13.3 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on LeMaitre Vascular and its competitors.
Is LeMaitre Vascular's Research & Development too high?
LeMaitre Vascular's current Research & Development is €13.3 Mil. Overall, LeMaitre Vascular has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's Research & Development compare to PLSE and XRAY?
LeMaitre Vascular's Research & Development of €13.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on LeMaitre Vascular and its competitors. LeMaitre Vascular's current Research & Development is €13.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (STU:LHU) is currently considered Modestly Undervalued. The stock's GF Value™ is €81.33, compared to a current price of €69.00 — trading 15.2% below its estimated fair value. The current Research & Development is €13.3 Mil. LeMaitre Vascular's overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For LeMaitre Vascular (STU:LHU), the current Research & Development is €13.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LeMaitre Vascular (STU:LHU) Overvalued in 2026?

Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued. The current stock price of €69.00 is trading 15.2% below its estimated GF Value™ of €81.33. GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.

Key valuation signals for STU:LHU:

  • Research & Development: €13.3 Mil
  • GF Value™: €81.33 vs. price of €69.00 (15.2% below fair value)
  • GF Score™: 98/100

No single metric tells the full story. See the STU:LHU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LeMaitre Vascular Business Description

Other Exchanges LMAT:USA
Address 63 Second Avenue, Burlington, MA, USA, 01803
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
98GF Score

Get the complete analysis for STU:LHU

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€69.00
Price
€81.33
GF Value